BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 billion
BioMarin Pharmaceutical (BMRN) has agreed to acquire Amicus Therapeutics (FOLD) for $14.50 per share
Keep reading this article with Yahoo Finance Plus Silver
Silver
- Premium news Full access to Financial Times and MT Newswires articles
- Stock picks Expert picks from Motley Fool, Zacks, and Moby
- Research reports Expert analysis from Morningstar and Argus
